Nonintegrating Lentivector Vaccines Stimulate Prolonged T-Cell and Antibody Responses and Are Effective in Tumor Therapy
- 1 April 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (7), 3094-3103
- https://doi.org/10.1128/jvi.02519-08
Abstract
Lentiviral vectors (lentivectors) are effective for stimulation of cell-mediated and humoral immunity following subcutaneous and intramuscular immunization. However, lentivector genome integration carries a risk of perturbation of host gene expression. Here, we demonstrate that lentivectors with multiple mutations that prevent integration are also effective immunogens. First, systemic CD8 + T-cell responses to the model antigen ovalbumin were detected following subcutaneous injection of nonintegrating lentivectors. Transfer of transgenic OT1 T cells demonstrated that antigen presentation persisted for at least 30 days. Furthermore, an enhanced CD8 + T-cell response, peaking at 7 days, was stimulated by coexpression of p38 MAP kinase or an NF-κB activator from the same vector. Second, we demonstrated systemic CD8 + T-cell and antibody responses to the secreted hepatitis B virus (HBV) surface antigen expressed from a nonintegrating lentivector injected intramuscularly. The induction, specificity, and kinetics of antibody production closely mimicked those of natural HBV infection. In this case, both the vector genome and the immune response were maintained for at least 2 months. Together, our data indicate that nonintegrating lentivectors can be employed to generate effective vaccines.Keywords
This publication has 32 references indexed in Scilit:
- Expression of vFLIP in a Lentiviral Vaccine Vector Activates NF-κB, Matures Dendritic Cells, and Increases CD8+T-Cell ResponsesJournal of Virology, 2009
- Immunization with a Lentiviral Vector Stimulates both CD4 and CD8 T Cell Responses to an Ovalbumin TransgeneMolecular Therapy, 2006
- Efficient Induction of Tumor Antigen–Specific CD8+ Memory T Cells by Recombinant LentivectorsCancer Research, 2006
- Immunodominance of Poxviral-Specific CTL in a Human Trial of Recombinant-Modified Vaccinia AnkaraPublished by The American Association of Immunologists ,2005
- Induction of Therapeutic Antitumor Immunity byIn VivoAdministration of a Lentiviral VaccineHuman Gene Therapy, 2005
- On Immunity Against Infections and Vaccines: Credo 2004Scandinavian Journal of Immunology, 2004
- A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cellsNature Immunology, 2004
- Novel Integrase-Defective Lentiviral Episomal Vectors for Gene TransferHuman Gene Therapy, 2004
- Intravenous Injection of a Lentiviral Vector Encoding NY-ESO-1 Induces an Effective CTL ResponsePublished by The American Association of Immunologists ,2004
- High-Level Transduction and Gene Expression in Hematopoietic Repopulating Cells Using a Human Imunodeficiency Virus Type 1-Based Lentiviral Vector Containing an Internal Spleen Focus Forming Virus PromoterHuman Gene Therapy, 2002